---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40095078.md"
description: "Summit Therapeutics, Compass Pathways, and Xortx Therapeutics are a few small-cap biopharma stocks: SMMT focuses on HER3-targeted tumors, CMPS works on psychedelic mental health therapies, and XRTX primarily targets gout nephropathy indications.All three are small-cap clinical-stage companies, high-risk and high-volatility, completely reliant on their respective clinical data for catalysts; they'll trade sideways or decline slightly without news."
datetime: "2026-04-22T10:40:50.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40095078.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40095078.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40095078.md)
author: "[漩涡激流](https://longbridge.com/en/profiles/26968421.md)"
---

# Summit Therapeutics, Compass Pathways, and Xortx T…


### Related Stocks

- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)
- [XRTX.US](https://longbridge.com/en/quote/XRTX.US.md)
- [300803.CN](https://longbridge.com/en/quote/300803.CN.md)
- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)